Evan J. Lipson, MD - Real Talk About Maximizing Care in Advanced Melanoma: Balancing Benefit and Risk Using Dual Immunotherapy Regimens
CME in Minutes: Education in Dermatology
by Answers in CME
1w ago
Please visit answersincme.com/AUY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the role of dual immunotherapeutic approaches to the management of advanced melanoma. Upon completion of this activity, participants should be better able to: Review the clinical goals of patients with advanced melanoma receiving immunotherapy-based treatment; Describe the long-term clinical profiles of dual immunotherapeutic approaches to the management of advanced melanoma; and Outline evidence-based, immun ..read more
Visit website
Jonathan Barker, BSc, MB, BS, MD, FRCP - Novel Approved and Emerging IL-36 Receptor Inhibitors for the Treatment of GPP
CME in Minutes: Education in Dermatology
by Answers in CME
1M ago
Please visit answersincme.com/PJR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, Jonathan Barker, BSc, MB, BS, MD, FRCP, an expert in dermatology, discusses unmet therapeutic needs in the treatment of generalized pustular psoriasis (GPP). Upon completion of this activity, participants should be better able to: Recognize the burden of generalized pustular psoriasis (GPP), including unmet therapeutic needs; Explain the rationale for the use of IL-36 receptor inhibitors in treating GPP; and Describe the clinical profiles o ..read more
Visit website
David M. Miller, MD, PhD / Kevin Emerick, MD - Coming Together to Improve Outcomes in Resectable Cutaneous Squamous Cell Carcinoma: Multidisciplinary Care Strategies With Neoadjuvant Immunotherapy
CME in Minutes: Education in Dermatology
by Answers in CME
1M ago
Please visit answersincme.com/ADB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the rationale and clinical data for incorporating neoadjuvant immunotherapy into the treatment of resectable cutaneous squamous cell carcinoma. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for incorporating neoadjuvant immunotherapy in the treatment of resectable CSCC; Describe the clinical impact of neoadjuvant immunotherapy in treating resectable CSCC ..read more
Visit website
Vishal A. Patel, MD - Making Headway in Treating Resectable Cutaneous Squamous Cell Carcinoma: Setting Sights on Neoadjuvant Immunotherapy
CME in Minutes: Education in Dermatology
by Answers in CME
2M ago
Please visit answersincme.com/JEX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses the role of neoadjuvant immunotherapy in the treatment of resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe the clinical impact of neoadjuvant immunotherapy in treating resectable CSCC; Outline evidence-based, patient-centered strategies to select an appropriate treatment approach for patients with resectable CSCC ..read more
Visit website
Trisha Wise-Draper, MD, PhD - Empowering Precision Decisions: PD-1 Inhibitor-Based Therapies and Biomarker Testing in R/M HNSCC
CME in Minutes: Education in Dermatology
by Answers in CME
4M ago
Please visit answersincme.com/EXA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma. Upon completion of this activity, participants should be better able to: Outline guideline-recommended approaches to the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) using PD-1 inhibitors; Review the latest clinical data for first-line PD-1 inhibitor–based t ..read more
Visit website
Shawn Kwatra, MD - Itching for Relief: Exploring the Role of Novel Biologics in Prurigo Nodularis
CME in Minutes: Education in Dermatology
by Answers in CME
5M ago
Please visit answersincme.com/SRG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in dermatology discuss the diagnosis and treatment of prurigo nodularis. Upon completion of this activity, participants should be better able to: Recognize the need for treatment intensification in patients with prurigo nodularis (PN), including patients of color, using novel biologic therapies; Review the clinical profiles of novel biologic therapies for PN; and Outline clinical factors that may facilitate the optimal use of biolog ..read more
Visit website
Sapna P. Patel, MD - Enhancing Neoadjuvant and Adjuvant Treatment in Resectable Melanoma: Is Timing the Key to Improved Outcomes?
CME in Minutes: Education in Dermatology
by Answers in CME
5M ago
Please visit answersincme.com/CAC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in melanoma discusses the use of neoadjuvant-adjuvant immunotherapy to improve outcomes in patients with resectable melanoma. Upon completion of this activity, participants should be better able to: Review the rationale for the use of neoadjuvant-adjuvant immunotherapy for patients with resectable melanoma; Describe the clinical profiles of the emerging neoadjuvant-adjuvant immunotherapeutic regimens in patients with resectable me ..read more
Visit website
Peter Lio, MD - Enriching Care for Pediatric Atopic Dermatitis: Evidence-Based Strategies for Integrating Targeted Systemic Therapies
CME in Minutes: Education in Dermatology
by Answers in CME
6M ago
Please visit answersincme.com/CQD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology provides a comprehensive update on the evidence-based use of targeted systemic therapies in pediatric patients with moderate-to-severe atopic dermatitis (AD). Upon completion of this activity, participants should be better able to: Recognize when initiation of systemic therapy may be warranted in pediatric patients with moderate-to-severe atopic dermatitis (AD); Describe the clinical profiles of targeted systemic th ..read more
Visit website
Leonard H. Calabrese, DO - Shingles Prevention Strategies in Immune-Mediated Diseases
CME in Minutes: Education in Dermatology
by Answers in CME
8M ago
Please visit answersincme.com/QNV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in immunology discusses shingles prevention strategies for patients with immune-mediated diseases. Upon completion of this activity, participants should be better able to: Recognize the risk factors and clinical burden of shingles; Evaluate the current recommendations and clinical evidence on shingles vaccination in patients with immune-mediated diseases; and Implement patient-centered, evidence-based strategies to improve shingle ..read more
Visit website
Dirk Schadendorf, MD - An Evolution in Care for Advanced Melanoma: Exploring the Clinical Implications of Approved and Emerging Anti–LAG-3/PD-1 Combinations
CME in Minutes: Education in Dermatology
by Answers in CME
8M ago
Please visit answersincme.com/ZUU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology and oncology discusses the clinical implications of approved and emerging anti–lymphocyte activation gene-3 (LAG-3)/programmed cell death protein 1 (PD-1) combinations in advanced melanoma. Upon completion of this activity, participants should be better able to: Outline the current unmet treatment needs for patients with advanced melanoma; Review the mechanism of action of anti–LAG-3/PD-1 combinations for the manage ..read more
Visit website

Follow CME in Minutes: Education in Dermatology on FeedSpot

Continue with Google
Continue with Apple
OR